(WST) West Pharmaceutical - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9553061055

Stock: Stoppers, Seals, Syringe, Cartridge, Vial

Total Rating 54

Risk 91

Buy Signal -0.24

Medical Instruments & Supplies +2.8
Health Care Supplies +0.4

Market Cap: 18,105m
Avg Trading Vol: 213M USD

ATR: 3.40%
Peers RS (IBD): 47.9

Risk 5d forecast
Volatility	42.7%
Relative Tail Risk	-30.1%

Reward TTM
Sharpe Ratio	0.24
Alpha	-0.26

Character TTM
Beta	0.253
Beta Downside	-0.174

Drawdowns 3y
Max DD	53.79%
CAGR/Max DD	-0.14

EPS (Earnings per Share)

EPS CAGR: -3.15%
EPS Trend: -44.9%

Last SUE: 1.10
Qual. Beats: 4

Revenue

Rev. CAGR: 3.03%
Rev. Trend: 46.8%

Last SUE: 0.45
Qual. Beats: 0

Description: WST West Pharmaceutical March 02, 2026

West Pharmaceutical Services (WST) designs, manufactures, and sells containment and delivery systems for injectable drugs across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company operates two segments: Proprietary Products, which provides stoppers, seals, syringe and cartridge components, self-injection devices, and related services to biologic, generic, and pharmaceutical firms; and Contract-Manufactured Products, which builds automated assemblies for surgical, diagnostic, ophthalmic, and other drug-delivery devices for pharma, diagnostics, and med-device customers.

In FY 2023 West generated $2.2 billion in revenue, up 5% year-over-year, with an adjusted EPS of $4.50 and operating cash flow of $520 million, reflecting strong demand for self-administration packaging amid a 6% CAGR growth projection for the global injectable market through 2028. Recent strategic moves include the acquisition of a self-injection device specialist in Q4 2023, expanding its portfolio in the fast-growing biologics segment, while macro-economic drivers such as an aging population and heightened focus on at-home therapies continue to boost order volumes.

For a deeper dive into West’s valuation metrics and how they compare within the Health-Care Supplies sector, you might find ValueRay’s analysis worth a quick look.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income: 493.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 3.39 > 1.0
NWC/Revenue: 43.05% < 20% (prev 34.14%; Δ 8.91% < -1%)
CFO/TA 0.18 > 3% & CFO 754.8m > Net Income 493.7m
Net Debt (-470.2m) to EBITDA (776.0m): -0.61 < 3
Current Ratio: 3.02 > 1.5 & < 3
Outstanding Shares: last quarter (72.7m) vs 12m ago -1.36% < -2%
Gross Margin: 35.89% > 18% (prev 0.35%; Δ 3555 % > 0.5%)
Asset Turnover: 77.68% > 50% (prev 79.40%; Δ -1.71% > 0%)
Interest Coverage Ratio: 102.5 > 6 (EBITDA TTM 776.0m / Interest Expense TTM 5.90m)

Altman Z'' 10.00

A: 0.31 (Total Current Assets 1.98b - Total Current Liabilities 654.9m) / Total Assets 4.27b
B: 1.02 (Retained Earnings 4.37b / Total Assets 4.27b)
C: 0.15 (EBIT TTM 604.6m / Avg Total Assets 3.96b)
D: 3.92 (Book Value of Equity 4.29b / Total Liabilities 1.09b)
Altman-Z'' Score: 10.52 = AAA

Beneish M -3.15

DSRI: 0.98 (Receivables 574.4m/552.5m, Revenue 3.07b/2.89b)
GMI: 0.97 (GM 35.89% / 34.65%)
AQI: 0.91 (AQ_t 0.11 / AQ_t-1 0.12)
SGI: 1.06 (Revenue 3.07b / 2.89b)
TATA: -0.06 (NI 493.7m - CFO 754.8m) / TA 4.27b)
Beneish M-Score: -3.15 (Cap -4..+1) = AA

What is the price of WST shares?

As of March 07, 2026, the stock is trading at USD 245.86 with a total of 889,151 shares traded.
Over the past week, the price has changed by -3.33%, over one month by -1.24%, over three months by -8.55% and over the past year by +6.00%.

Is WST a buy, sell or hold?

West Pharmaceutical has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WST.

StrongBuy: 10
Buy: 2
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the WST price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	318.4	29.5%
Analysts Target Price	318.4	29.5%

WST Fundamental Data Overview March 05, 2026

P/E Trailing = 37.0221
P/E Forward = 33.4448
P/S = 5.8895
P/B = 5.6975
P/EG = 3.1006
Revenue TTM = 3.07b USD
EBIT TTM = 604.6m USD
EBITDA TTM = 776.0m USD
Long Term Debt = 202.8m USD (from longTermDebt, last quarter)
Short Term Debt = 22.7m USD (from shortTermDebt, last quarter)
Debt = 321.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -470.2m USD (from netDebt column, last quarter)
Enterprise Value = 17.63b USD (18.10b + Debt 321.1m - CCE 791.3m)
Interest Coverage Ratio = 102.5 (Ebit TTM 604.6m / Interest Expense TTM 5.90m)
EV/FCF = 37.61x (Enterprise Value 17.63b / FCF TTM 468.9m)
FCF Yield = 2.66% (FCF TTM 468.9m / Enterprise Value 17.63b)
FCF Margin = 15.26% (FCF TTM 468.9m / Revenue TTM 3.07b)
Net Margin = 16.06% (Net Income TTM 493.7m / Revenue TTM 3.07b)
Gross Margin = 35.89% ((Revenue TTM 3.07b - Cost of Revenue TTM 1.97b) / Revenue TTM)
Gross Margin QoQ = 37.75% (prev 36.49%)
Tobins Q-Ratio = 4.13 (Enterprise Value 17.63b / Total Assets 4.27b)
Interest Expense / Debt = 1.65% (Interest Expense 5.30m / Debt 321.1m)
Taxrate = 20.13% (33.3m / 165.4m)
NOPAT = 482.9m (EBIT 604.6m * (1 - 20.13%))
Current Ratio = 3.02 (Total Current Assets 1.98b / Total Current Liabilities 654.9m)
Debt / Equity = 0.10 (Debt 321.1m / totalStockholderEquity, last quarter 3.18b)
Debt / EBITDA = -0.61 (Net Debt -470.2m / EBITDA 776.0m)
Debt / FCF = -1.00 (Net Debt -470.2m / FCF TTM 468.9m)
Total Stockholder Equity = 2.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.48% (Net Income 493.7m / Total Assets 4.27b)
RoE = 16.68% (Net Income TTM 493.7m / Total Stockholder Equity 2.96b)
RoCE = 19.12% (EBIT 604.6m / Capital Employed (Equity 2.96b + L.T.Debt 202.8m))
RoIC = 15.27% (NOPAT 482.9m / Invested Capital 3.16b)
WACC = 6.75% (E(18.10b)/V(18.43b) * Re(6.85%) + D(321.1m)/V(18.43b) * Rd(1.65%) * (1-Tc(0.20)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.55%
[DCF] Terminal Value 82.43% ; FCFF base≈391.9m ; Y1≈378.4m ; Y5≈373.5m
[DCF] Fair Price = 127.7 (EV 8.73b - Net Debt -470.2m = Equity 9.20b / Shares 72.0m; r=6.75% [WACC]; 5y FCF grow -4.67% → 2.90% )
EPS Correlation: -44.92 | EPS CAGR: -3.15% | SUE: 1.10 | # QB: 4
Revenue Correlation: 46.75 | Revenue CAGR: 3.03% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.99 | Chg7d=+0.041 | Chg30d=+0.041 | Revisions Net=+7 | Analysts=12
EPS current Year (2026-12-31): EPS=7.98 | Chg7d=+0.212 | Chg30d=+0.222 | Revisions Net=+12 | Growth EPS=+9.4% | Growth Revenue=+5.7%
EPS next Year (2027-12-31): EPS=8.84 | Chg7d=+0.011 | Chg30d=+0.045 | Revisions Net=+3 | Growth EPS=+10.8% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +1.00 (7 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.2% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = +1.7% (Analyst 7.0% - Implied 5.2%)

Additional Sources for WST Stock

Fund Manager Positions: Dataroma | Stockcircle